Journal article

Melphalan modifies the bone microenvironment by enhancing osteoclast formation.

Ryan C Chai, Michelle M McDonald, Rachael L Terry, Nataša Kovačić, Jenny M Down, Jessica A Pettitt, Sindhu T Mohanty, Shruti Shah, Gholamreza Haffari, Jiake Xu, Matthew T Gillespie, Michael J Rogers, John T Price, Peter I Croucher, Julian MW Quinn

Oncotarget | Published : 2017

Abstract

Melphalan is a cytotoxic chemotherapy used to treat patients with multiple myeloma (MM). Bone resorption by osteoclasts, by remodeling the bone surface, can reactivate dormant MM cells held in the endosteal niche to promote tumor development. Dormant MM cells can be reactivated after melphalan treatment; however, it is unclear whether melphalan treatment increases osteoclast formation to modify the endosteal niche.Melphalan treatment of mice for 14 days decreased bone volume and the endosteal bone surface, and this was associated with increases in osteoclast numbers. Bone marrow cells (BMC) from melphalan-treated mice formed more osteoclasts than BMCs from vehicle-treated mice, suggesting th..

View full abstract

University of Melbourne Researchers